Literature DB >> 1914424

Histopathological findings in a case of systemic lupus erythematosus-associated anti-phospholipid syndrome.

P L Meroni1, R Rivolta, P Ghidoni.   

Abstract

The vessel anatomopathological lesions in a patient with systemic lupus erythematosus associated anti-phospholipid syndrome are described. Vasculitic lesions were nearly absent but small vessels showed hyalin thrombosis or substenosis due to subendothelial deposition of amorphous PAS-positive material in different anatomical districts. These findings can be related to the patient's clinical manifestations, particularly the central nervous system involvement and can be discussed regarding the possible pathogenetic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914424     DOI: 10.1007/bf02207667

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  The neurological manifestations of systemic lupus erythematosus.

Authors:  R T Johnson; E P Richardson
Journal:  Medicine (Baltimore)       Date:  1968-07       Impact factor: 1.889

2.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

Review 3.  Lupus anticoagulants.

Authors:  S S Shapiro; P Thiagarajan
Journal:  Prog Hemost Thromb       Date:  1982

4.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

5.  Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.

Authors:  M D Lockshin; M L Druzin; S Goei; T Qamar; M S Magid; L Jovanovic; M Ferenc
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

6.  Cerebral and retinal vascular changes in systemic lupus erythematosus.

Authors:  E M Graham; D J Spalton; R O Barnard; A Garner; R W Russell
Journal:  Ophthalmology       Date:  1985-03       Impact factor: 12.079

7.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome.

Authors:  R A Asherson; M A Khamashta; A Gil; J J Vazquez; O Chan; E Baguley; G R Hughes
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965

8.  Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity.

Authors:  P L Meroni; E N Harris; A Brucato; A Tincani; W Barcellini; A Vismara; G Balestrieri; G R Hughes; C Zanussi
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

9.  Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  A Vismara; P L Meroni; A Tincani; E N Harris; W Barcellini; A Brucato; M Khamashta; G R Hughes; C Zanussi; G Balestrieri
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

10.  Obstetric complications associated with the lupus anticoagulant.

Authors:  D W Branch; J R Scott; N K Kochenour; E Hershgold
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

View more
  4 in total

Review 1.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

2.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

3.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

4.  Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus.

Authors:  C T Ravirajan; I Harmer; T McNally; A Hohmann; C G Mackworth-Young; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1995-06       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.